丹参川芎嗪注射液联合低分子肝素预防骨科相关疾病下肢深静脉血栓的Meta分析

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (0 KB) HTML (44 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To systematically evaluate the effect and safety of Salviae Miltiorrhizae and Ligustrazine Hydrochloride Injection combined with Low Molecular Weight Heparin in preventing lower extremity deep venous thrombosis associated with orthopedic diseases. Methods The randomized controlled clinical trials were retrieved related to Salviae Miltiorrhizae and Ligustrazine Hydrochloride Injection combined with Low Molecular Weight Heparin (combination group) versus Low Molecular Weight Heparin (control group) used to prevent orthopedic related diseases in the prevention of lower limb deep vein thrombosis by computer in China Biology Medicine (CBM)，China National Knowledge Internet (CNKI)，VIP database (VIP)，Wanfang database，PubMed，Embase，Cochrane Library，Web of Science and other databases. The time was from the establishment of the database to November 2019. Documents were selected according to the inclusion and exclusion criteria，the methodological quality of the included studies was strictly evaluated and data were extracted，and Meta analysis was performed using RevMan 5.3. Results A total of 955 patients were enrolled in 11 studies. Meta analysis results showed that the incidence of deep vein thrombosis，Ddimer，and plasma activated partial thrombin time after treatment in the combination group were better than those in the control group，and the differences were statistically significant (P＜0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P＞0.05). Conclusion The application of Salviae Miltiorrhizae and Ligustrazine Hydrochloride Injection combined with Low Molecular Weight Heparin can effectively improve the blood hypercoagulability and prevent the incidence of deep vein thrombosis，and it is safe and does not increase the adverse reactions，which is worth clinical promotion.

Key words： Salviae Miltiorrhizae and Ligustrazine Hydrochloride Injection Low Molecular Weight Heparin Deep venous thrombosis Fracture Joint replacement Meta-analysis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Chao-ming
	LIN Tian-ye2
	YANG Peng
	XU Jing-li
	XIONG Bing-lang
	ZOU Qi-zhao
	LAI Qi-zhong
	ZHANG Qing-wen

Cite this article:

ZHANG Chao-ming,LIN Tian-ye2,YANG Peng, et al. Meta-analysis of Salviae Miltiorrhizae and Ligustrazine Hydrochloride Injection combined with Low Molecular Weight Heparin in preventing lower extremity deep venous thrombosis associated with orthopedic diseases[J]. 中国当代医药, 2020, 27(18): 4-8.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I18/4

［1］	张红，孟令玉.人工关节置换术后下肢深静脉血栓形成的彩色多普勒超声诊断［J］.临床医药文献电子杂志，2019，6（71）：150，153.
［2］	Song K，Yao Y，Rong Z，et al.The preoperative incidence of deep vein thrombosis （DVT）and its correlation with postoperative DVT in patients undergoing elective surgery for femoral neck fractures［J］.Arch Orthop Trauma Surg，2016，136（10）：1459-1464.
［3］	Liu J，Liu P，Xia K，et al.Iliac vein compression syndrome（IVCS）：an under-recognized risk factor for left-sided deep venous thrombosis （DVT） in old hip fracture patients［J］.Med Sci Monit，2017，23（8）：2078-2082.
［4］	Tang Y，Wang K，Shi Z，et al.A RCT study of Rivaroxaban，low-molecular-weight heparin，and sequential medication regimens for the prevention of venous thrombosis after internal fixation of hip fracture［J］.Biomed Pharmacother，2017，92（10）：982-988.
［5］	Jadad AR，Moor RA，Carroll D，et al.Assessing the quality of reports of randomized clinical trialss blinding necessary［J］.Controlled Clin Trials，1996，17（9）：1-12.
［6］	冯建宏，刘文操.丹参川芎嗪联合低分子肝素预防老年髋关节周围骨折下肢深静脉血栓形成的临床研究［J］.世界中西医结合杂志，2014，9（8）：867-869.
［7］	程华斌.丹参川芎嗪联合低分子肝素预防下肢骨折术后深静脉血栓形成的临床疗效［J］.中国社区医师，2016，32（7）：99-100.
［8］	王丽平.丹参川芎嗪与低分子肝素预防下肢骨折术后深静脉血栓形成疗效观察［J］.内蒙古中医药，2017，36（7）：19.
［9］	郑勇，马木提江，秦承东，等.丹参川芎嗪与低分子肝素预防下肢骨折术后深静脉血栓形成疗效观察［J］.世界中西医结合杂志，2014，9（9）：967-969.
［10］	许超，彭宗生，魏芳，等.丹参川芎嗪注射液对股骨骨折保守治疗患者凝血功能及D-二聚体的影响［J］.临床军医杂志，2015，43（10）：1089-1090.
［11］	解朋涛，江渟.丹参川芎嗪注射液联合低分子肝素钙预防髋部骨折术后下肢深静脉血栓形成临床观察［J］.实用中医药杂志，2016，32（11）：1093-1094.
［12］	梁翠霞，黄定根.丹参川芎嗪注射液用于骨折围术期治疗的安全性和有效性评价［J］.中国药业，2017，26（2）：67-69.
［13］	彭宗生，许超，魏芳，等.丹参川芎嗪注射液预防股骨近端骨折患者术后DVT 效果观察［J］.山东医药，2016，56（16）：70-72.
［14］	田玉军.低分子肝素联合丹参川芎嗪预防髋部骨折术后深静脉血栓形成临床观察［J］.实用中医药杂志，2017，33（9）：1065-1066.
［15］	刘腾鸿.丹参川芎嗪注射液对预防人工膝关节置换术后深静脉血栓的临床研究［D］.福州：福建中医药大学，2013.
［16］	刘海民.丹参川芎嗪联合低分子肝素预防老年髋关节周围骨折下肢深静脉血栓形成临床研究［J］.医药前沿，2016，6（20）：298-299.
［17］	苏明华，周亚光，杨光田.川芎嗪对原代培养大鼠海马神经元L 型钙通道电流和胞浆内钙浓度的影响［J］.中国康复，2008，23（1）：17-19.
［18］	Yang RX，Huang SY，Yan FF，et al.Danshensu protects vascular endotheliain a rat model of hyperhomocysteinemia［J］.Acta Pharmacol Sin，2010，31（10）：1395-1400.
［19］	冯小辉.利伐沙班与低分子肝素预防关节置换术后下肢静脉血栓形成的效果分析［J］.海峡药学，2019，31（1）：214-215.
［20］	刘广东，赵志辉，杨志强，等.低分子肝素联合血塞通在老年髋部骨折术后的作用［J］.中国老年学杂志，2019，39（1）：92-95.